June 23, 2016 11:07 AM Eastern Daylight Time
DAVIS, Calif.--(BUSINESS WIRE)--Gold Standard Diagnostics, Corp. (GSD) announced today a strategic alliance with R-Biopharm AG (Darmstadt, Germany) to collaborate on multiple technology and marketing initiatives that will leverage the companies’ respective strengths in expanding product offerings and geographic sales coverage.
Under this arrangement, GSD will be the exclusive distributor for R-Biopharm’s Clinical diagnostics products in the U.S. GSD has broad U.S. market coverage, through its national channel partners, in key clinical segments that include hospitals, POL’s and reference laboratories. This initiative expands GSD’s strategic vision of collaborating with technology leaders in bringing differentiated solutions to the market by adding content to GSD’s automated instrument platforms.
R-Biopharm has a broad portfolio of products, in multiple technology formats, which are complementary to GSD’s expertise in instrument development. This partnership will give R-Biopharm access to GSD products, including its instrumentation platforms and diagnostic test kits, to enhance their offering to their worldwide distribution network spread over 130 countries.
The two companies will also collaborate on several strategic projects for the U.S. and International markets that will leverage their respective strengths in developing transformative technologies that establish strong market niches. R-Biopharm’s network of subsidiaries and GSD’s select supplier base will present opportunities that will drive innovative concepts in delivering diagnostic solutions. GSD will also add to this partnership with its expertise in clearing products through the FDA.
John Griffiths, CEO of GSD, comments “We look forward to partnering with R-Biopharm, who has a strong track record of growing their business organically and through strategic acquisitions. RBIO is a globally-recognized leader in developing assays for the Clinical Diagnostics and Food & Feed testing markets. This alliance will also fast track innovation and investment in new technologies.”
Ralf Dreher, CEO of R-Biopharm, said “The partnership between R-Biopharm and Gold Standard Diagnostics will enable both companies to strengthen their position as solution providers in North America and the Global Market. GSD has an outstanding reputation in clinical business in the USA and can look back on many years of experience in laboratory equipment and automation. The synergy born out of this cooperation will set new standards in clinical diagnostics, which will also be highly beneficial for the customer.”
About Gold Standard Diagnostics, Corp.
Gold Standard Diagnostics, Corp., is a privately held clinical diagnostics company based in Davis, California. The company develops, manufactures and distributes an innovative portfolio of instrumentation and diagnostic products to clinical laboratories Worldwide. Since launching the ThunderBolt in 2012, GSD has released 4 new instrumentation platforms, with over 600 installations, including an open EIA+CLIA combination instrument, and the AIX1000, the first fully automated system for performing RPR (Rapid Plasma Reagin) syphilis tests. With many projects in the pipeline, the next expected launch is of the Bolt, a one plate open system to meet the needs of low volume customers. GSD also develops and offers an extensive menu of serology tests used in the areas of autoimmune disease, infectious disease and endocrinology, and is continuously building its pipeline of innovative products.
About R-Biopharm AG
R-Biopharm possesses many years of sound experience in the Clinical diagnostics market, particularly in the field of infectious stool diagnostics as well as in the field of serological infection diagnostics and allergy diagnostics. In 2006 the clinical product portfolio was extended by innovative test systems in the tumor diagnostics and gastroenterology product lines. R-Biopharm is a successful global player and is constantly developing new and groundbreaking test systems in different areas, Process automation being a main focus from the beginning. All distributed tests are validated and CE-marked.R-Biopharm’s distinctive policy of partnership and teamwork is an approach valued by its customers and research partners alike. The company’s key objective is to be a dependable point of contact for customers, providing competent advice on every sector it serves.At R-Biopharm the future is set to offer further exciting prospects in the fields of clinical diagnostics and food and feed analysis. The foremost challenge is to advance the development of new and versatile fast tests. These will shorten the time it takes to obtain results from a wide range of analytical procedures.
DAVIS, California, (March 7, 2016) — Gold Standard Diagnostics, Corp. announced today that the U.S. Food and Drug Administration issued a 510(k) clearance for the AIX1000TM Rapid Plasma Reagin (RPR) Automated Test System. The AIX1000TM is a fully automated system for RPR syphilis testing.
The AIX1000TM system fully automates the RPR test procedure from sample loading to result interpretation for titers and screens. Digital images of each result are retrievable on demand, for review anytime. Interpretation of results is completed by a pattern-recognition algorithm that is both objective and consistent.
John Griffiths, CEO said, “We are excited to bring this new, innovative technology to clinical laboratories. The AIX1000TM automates a test that has historically been manual, labor intensive and subjective. This fully automated solution allows laboratories to continue to perform the traditional syphilis testing algorithm while improving efficiencies and reducing costs. RPR is now fully automated with all of the features and benefits of an immunoassay processor.”
Gold Standard Diagnostics, Corp. is a privately held clinical diagnostics company based in Davis, California. The company develops, manufactures and distributes a portfolio of instrumentation and diagnostic products to clinical laboratories in the U.S., EMEA, Asia, and South America. Current product offerings include the Thunderbolt® instrument, an open format platform for enzyme and chemiluminescence immunoassays, and an extensive menu of serology tests used in the areas of autoimmune disease, infectious disease and endocrinology.
The 2015 AACC Clinical Lab Expo was another great year for Gold Standard Diagnostics.
We will be following up on the many great meetings and contacts made during the event over the next few weeks.
In the meantime, please don't hesitate to contact us with any questions you may have about our instrumentation, reagents, service or company in general.
June 19, 2013, Davis, CA – Gold Standard Diagnostics, Corp. (GSD, www.gsdx.us), a leading manufacturer and marketer of clinical laboratory instrumentation and assays for the in vitro diagnostics market, announces new Line Immunoassay technology for Lyme confirmation testing. GSD gives clinical laboratories an FDA cleared, improved option for serological confirmation testing for Lyme disease according to the CDC-recommended two-step process. Both the IgG and IgM line blots are substantially equivalent to traditional Western Blot technology, but offer advancements in usability and objectivity through use of Line Immunoassay technology. GSD's LIA test strips offer numerous enhancements including: improved sensitivity and specificity, consistent results, large lot sizes, easier handling and automation options.
"The demands of today's clinical laboratories require consistent, reliable and user-friendly products," said John Griffiths, CEO of Gold Standard Diagnostics. GSD's innovative
Davis, CA, March 19th, 2013 – Gold Standard Diagnostics, Corp. (GSD, www.gsdx.us), a leading manufacturer and marketer of clinical laboratory instrumentation and assays for the in vitro diagnostics market, today announced it has established distribution partnerships for the ThunderBolt® Automated Immunoassay Analyzer in 18 countries throughout Europe, Latin America, Asia and the Middle East since the official global launch in early 2012. ThunderBolt® sales in the U.S. market also continue to grow as laboratories recognize the powerful and seamless automation solutions that Gold Standard Diagnostics offers.
Mature and emerging markets alike have responded to the comprehensive suite of fully automated features that the compact and cost-effective ThunderBolt® offers. As a result, the global sales and marketing network has grown substantially over the past year. Established markets, such as those in Europe, have widely accepted the ThunderBolt® with installations in Germany, Spain, Finland, Austria, Switzerland and Belgium. Additional countries with installed units include South Korea, Mexico, Vietnam, and Puerto Rico. Distribution partnerships and sales in China, Brazil, India and Canada are also imminent.
November 14th, 2012, Davis, CA – Simplify parasitology testing with Gold Standard Diagnostics’ (GSD) comprehensive line of assays for parasites and worms. GSD’s extensive portfolio of parasite tests provides laboratories with a reliable,